The drive to minimize investment risk prior to clinical proof-of-concept demands new approaches to the development of therapeutic proteins, production cell lines, and manufacturing and related processes. Working in concert, Regeneron's scientists and Process Development and Industrial Operations groups have developed a means to significantly accelerate therapeutic protein development timelines in general and Traps and antibody development timelines in particular.

With regard to Antibodies, Regeneron scientists have created a novel series of technologies that streamline and automate isolation of antigen-specific, antibody-producing cells; cloning of antibody gene sequences; and creation of cell lines capable of producing antibodies. These technologies, coupled with Regeneron's extensive cell culture facilities for preclinical, clinical, and commercial manufacturing, enable the Company's engine for antibody development. Our team has a proven track record of taking lead candidates from gene cloning through scale-up of protein manufacturing to the 10,000 L bioreactor scale.